塞库金单抗
乌斯特基努马
医学
银屑病面积及严重程度指数
银屑病
随机对照试验
安全概况
皮肤病科
内科学
胃肠病学
不利影响
银屑病性关节炎
疾病
英夫利昔单抗
作者
Min‐Geol Lee,Yu‐Huei Huang,Joo‐Heung Lee,Seung‐Chul Lee,Tae‐Gyun Kim,Derrick Chen‐Wee Aw,Weibin Bao,Cathleen Michelle A. Dee,Adriana Guana,Tsen‐Fang Tsai
标识
DOI:10.1111/1346-8138.15004
摘要
Abstract The 52‐week results from the CLEAR ( NCT 02074982) study showed high and superior efficacy of secukinumab versus ustekinumab in clearing skin and improving patient‐reported outcomes, with comparable safety profile in subjects with moderate to severe psoriasis. Here, we analyzed the efficacy and safety of secukinumab in Asian subjects from the CLEAR study. In this double‐blind, phase III b study, eligible subjects with moderate to severe plaque psoriasis were randomized (1:1) to receive s.c. injection of secukinumab 300 mg or ustekinumab as per label. Of 62 subjects included in Asian subanalyses, 23 were randomized to secukinumab and 39 to ustekinumab. A significantly higher proportion of subjects achieved 90% or more improvement in Psoriasis Area and Severity Index ( PASI 90) with secukinumab versus ustekinumab at week 16 (78.3% vs 35.9%, P = 0.0010) and at week 52 (60.9% vs 33.3%, P = 0.0196). Similarly, a higher proportion of subjects achieved PASI 100 with secukinumab versus ustekinumab at week 16 (43.5% vs 10.3%, P = 0.0029) and at week 52 (30.4% vs 12.8%, P = 0.0704). The median time to achieve 50% improvement in baseline PASI was 2.8 weeks in the secukinumab group versus 6.3 weeks in the ustekinumab group. The safety profile of secukinumab was in line with the known profile and no deaths occurred. Overall, 95.7% and 84.6% of subjects remained on secukinumab and ustekinumab, respectively. Similar to the core study, secukinumab showed sustained and superior efficacy with faster response versus ustekinumab, and no new or unexpected safety concerns were identified, in Asian subjects with moderate to severe plaque psoriasis.
科研通智能强力驱动
Strongly Powered by AbleSci AI